Sybille KrauÃ

List of Publications by Year
in descending order

37 papers	2,098 citations	304743 22 h-index	345221 36 g-index
38 all docs	38 docs citations	38 times ranked	3653 citing authors

#	Article	IF	Citations
1	Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21830-21835.	7.1	360
2	MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nature Genetics, 2001, 29, 287-294.	21.4	264
3	Inhibition of Stat3â€mediated astrogliosis ameliorates pathology in an Alzheimer's disease model. EMBO Molecular Medicine, 2019, 11, .	6.9	186
4	Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death and Disease, 2013, 4, e752-e752.	6.3	129
5	Metformin lowers Ser-129 phosphorylated Î±-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death and Disease, 2014, 5, e1209-e1209.	6.3	116
6	FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Human Molecular Genetics, 2011, 20, 2928-2941.	2.9	87
7	Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1â€“PP2A protein complex. Nature Communications, 2013, 4, 1511.	12.8	84
8	Control of mTORC1 signaling by the Opitz syndrome protein MID1. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8680-8685.	7.1	82
9	The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex. PLoS ONE, 2014, 9, e102420.	2.5	74
10	Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. Scientific Reports, 2017, 7, 13753.	3.3	67
11	Metformin reverses early cortical network dysfunction and behavior changes in Huntingtonâ€™s disease. ELife, 2018, 7, .	6.0	64
12	A validated antibody panel for the characterization of tau post-translational modifications. Molecular Neurodegeneration, 2017, 12, 87.	10.8	61
13	Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathologica, 2015, 130, 619-631.	7.7	58
14	Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease. Journal of Molecular Biology, 2019, 431, 1869-1877.	4.2	57
15	Protein Phosphatase 2A and Rapamycin Regulate the Nuclear Localization and Activity of the Transcription Factor GLI3. Cancer Research, 2008, 68, 4658-4665.	0.9	50
16	A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling. Molecular Cancer, 2014, 13, 146.	19.2	34
17	Inhibition of the MID1 protein complex: a novel approach targeting APP protein synthesis. Cell Death Discovery, 2018, 4, 4.	4.7	33
18	The MID1 protein is a central player during development and in disease. Frontiers in Bioscience - Landmark, 2016, 21, 664-682.	3.0	30

#	Article	IF	Citations
19	Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder. ACS Chemical Neuroscience, 2018, 9, 1399-1408.	3.5	29
20	PPARÎ´ Is a Type 1 IFN Target Gene and Inhibits Apoptosis in T Cells. Journal of Investigative Dermatology, 2008, 128, 1940-1949.	0.7	25
21	Point Mutations in GLI3 Lead to Misregulation of its Subcellular Localization. PLoS ONE, 2009, 4, e7471.	2.5	23
22	The E3 Ubiquitin Ligase MID1 Catalyzes Ubiquitination and Cleavage of Fu. Journal of Biological Chemistry, 2014, 289, 31805-31817.	3.4	23
23	Regulation of the MID1 protein function is fine-tuned by a complex pattern of alternative splicing. Human Genetics, 2004, 114, 541-552.	3.8	22
24	Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs. Frontiers in Cellular Neuroscience, 2016, 10, 226.	3.7	22
25	MicroRNAs miR-19, miR-340, miR-374 and miR-542 regulate MID1 protein expression. PLoS ONE, 2018, 13, e0190437.	2.5	20
26	Upregulation of miR-370 and miR-543 is associated with reduced expression of heat shock protein 40 in spinocerebellar ataxia type 3. PLoS ONE, 2018, 13, e0201794.	2.5	19
27	Prions<i>Ex Vivo</i>: What Cell Culture Models Tell Us about Infectious Proteins. International Journal of Cell Biology, 2013, 2013, 1-14.	2.5	16
28	Huntingtin and Its Role in Mechanisms of RNA-Mediated Toxicity. Toxins, 2021, 13, 487.	3.4	12
29	Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients. MicroRNA (Shariqah, United Arab Emirates), 2018, 8, 76-85.	1.2	11
30	Pharmacological disruption of the MID1/Î±4 interaction reduces mutant Huntingtin levels in primary neuronal cultures. Neuroscience Letters, 2018, 673, 44-50.	2.1	9
31	The Role of MicroRNAs in Spinocerebellar Ataxia Type 3. Journal of Molecular Biology, 2019, 431, 1729-1742.	4.2	9
32	The MID1 Protein: A Promising Therapeutic Target in Huntingtonâ€™s Disease. Frontiers in Genetics, 2021, 12, 761714.	2.3	7
33	In vivo targeting of miRâ€223 in experimental eosinophilic oesophagitis. Clinical and Translational Immunology, 2020, 9, e1210.	3.8	3
34	Role and Perspective of Molecular Simulation-Based Investigation of RNAâ€“Ligand Interaction: From Small Molecules and Peptides to Photoswitchable RNA Binding. Molecules, 2021, 26, 3384.	3.8	3
35	FOXO1 controls protein synthesis and transcript abundance of mutant polyglutamine proteins, preventing protein aggregation. Human Molecular Genetics, 2021, 30, 996-1005.	2.9	2
36	Effects of heterochronic, non-myeloablative bone marrow transplantation on age-related behavioural changes in mice. Mechanisms of Ageing and Development, 2020, 191, 111327.	4.6	1

#	Article	IF	Citations
37	Huntingtonâ€™s Disease and Neurodegeneration. , 2021, , 1-23.		0